BR112020021269A2 - Construções de anticorpo anti-ror - Google Patents

Construções de anticorpo anti-ror Download PDF

Info

Publication number
BR112020021269A2
BR112020021269A2 BR112020021269-5A BR112020021269A BR112020021269A2 BR 112020021269 A2 BR112020021269 A2 BR 112020021269A2 BR 112020021269 A BR112020021269 A BR 112020021269A BR 112020021269 A2 BR112020021269 A2 BR 112020021269A2
Authority
BR
Brazil
Prior art keywords
domain
antigen
amino acid
ror
binding molecule
Prior art date
Application number
BR112020021269-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Lucas Bailey
Qufei Li
Malgorzata Agnieszka Nocula-Lugowska
Bryan Glaser
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of BR112020021269A2 publication Critical patent/BR112020021269A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112020021269-5A 2018-04-18 2019-04-18 Construções de anticorpo anti-ror BR112020021269A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659635P 2018-04-18 2018-04-18
US62/659,635 2018-04-18
PCT/US2019/028051 WO2019204564A1 (en) 2018-04-18 2019-04-18 Anti-ror antibody constructs

Publications (1)

Publication Number Publication Date
BR112020021269A2 true BR112020021269A2 (pt) 2021-03-16

Family

ID=68239890

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021269-5A BR112020021269A2 (pt) 2018-04-18 2019-04-18 Construções de anticorpo anti-ror

Country Status (15)

Country Link
US (2) US12084496B2 (https=)
EP (1) EP3797122A4 (https=)
JP (3) JP2021522162A (https=)
KR (1) KR20200143470A (https=)
CN (1) CN112384533A (https=)
AU (1) AU2019256431B2 (https=)
BR (1) BR112020021269A2 (https=)
CA (1) CA3097704A1 (https=)
EA (1) EA202092202A1 (https=)
IL (2) IL316574A (https=)
MX (4) MX2020010881A (https=)
MY (1) MY207121A (https=)
PH (1) PH12020551716A1 (https=)
SG (1) SG11202010235QA (https=)
WO (1) WO2019204564A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177805B (zh) * 2016-10-19 2024-04-02 英温拉公司 抗体构建体
EP4200336A4 (en) * 2020-08-24 2024-09-25 Epimab Biotherapeutics (HK) Limited Anti-ror1 antibodies and related bispecific binding proteins
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
US20230295276A1 (en) * 2022-03-18 2023-09-21 Novascope Biochips Inc. Antibody for porcine reproductive and respiratory syndrome virus and uses thereof
CA3259758A1 (en) * 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
WO2024207177A1 (en) * 2023-04-04 2024-10-10 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
KR20240016216A (ko) * 2022-07-26 2024-02-06 (주)에임드바이오 항-ror1 항체 및 이의 용도
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
GB202216284D0 (en) * 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
WO2025019791A1 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Activatable ror binding agents and uses thereof
AU2024292307A1 (en) * 2023-07-20 2026-01-29 Exelixis, Inc. Tyrosine-protein kinase membrane receptor 1 (ror1) antibody-drug conjugates and uses thereof
WO2025019780A1 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses thereof
WO2025132812A1 (en) * 2023-12-20 2025-06-26 Antalgenics, S.L. Phospholipase c inhibitor peptides and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
CA2759733C (en) * 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
US9242014B2 (en) * 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2657970T3 (es) * 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
CA2963696A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
US11673957B2 (en) * 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
SG11201806121PA (en) * 2016-01-20 2018-08-30 Scripps Research Inst Ror2 antibody compositions and related methods
TW201734049A (zh) 2016-01-22 2017-10-01 健生生物科技公司 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
CN110177805B (zh) 2016-10-19 2024-04-02 英温拉公司 抗体构建体
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Also Published As

Publication number Publication date
AU2019256431A1 (en) 2020-11-05
MX2025001906A (es) 2025-04-02
KR20200143470A (ko) 2020-12-23
IL316574A (en) 2024-12-01
CN112384533A (zh) 2021-02-19
EA202092202A1 (ru) 2021-07-23
US12084496B2 (en) 2024-09-10
US20210155692A1 (en) 2021-05-27
SG11202010235QA (en) 2020-11-27
EP3797122A4 (en) 2022-04-20
MY207121A (en) 2025-01-31
WO2019204564A9 (en) 2019-12-12
EP3797122A1 (en) 2021-03-31
MX2025001902A (es) 2025-04-02
MX2025001900A (es) 2025-04-02
US20240392002A1 (en) 2024-11-28
JP2025137618A (ja) 2025-09-19
CA3097704A1 (en) 2019-10-24
JP2023168551A (ja) 2023-11-24
IL278061A (en) 2020-11-30
WO2019204564A1 (en) 2019-10-24
JP2021522162A (ja) 2021-08-30
AU2019256431B2 (en) 2026-01-15
PH12020551716A1 (en) 2021-07-26
MX2020010881A (es) 2020-11-09

Similar Documents

Publication Publication Date Title
US20240392002A1 (en) Anti-ror antibody constructs
JP7591015B2 (ja) 抗体構築物
JP6366195B2 (ja) 炎症性疾患の予防又は治療剤
BR112020021279A2 (pt) Constructos de anticorpos trispecíficos trivalentes
TW202246322A (zh) 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
US20220213225A1 (en) Multispecific treg binding molecules
US20210163594A1 (en) Binding molecules
CA3213285A1 (en) Bioengineered immunomodulatory fusion protein compositions
TW202128752A (zh) 抗ｉｌ﹘２７抗體及其用途
CN113166248A (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
WO2021213245A1 (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20220153844A1 (en) Multispecific treg binding molecules
CN117412767A (zh) C-x-c基序趋化因子受体6（cxcr6）结合分子及其使用方法
AU2026202585A1 (en) Anti-ror antibody constructs
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
EA048615B1 (ru) Конструкции антител к ror
TW202608923A (zh) Ｌｔｂｒ結合分子及其用途
HK40064218B (zh) 抗gal3抗体及其用途

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]